{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:10:35Z","timestamp":1794352235428,"version":"4.9.0"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI18\/00171"],"award-info":[{"award-number":["PI18\/00171"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-41660-7","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T02:15:17Z","timestamp":1772849717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrating circulating microRNAs with epidemiological factors enhances breast cancer detection across subtypes: the MCC-Spain study"],"prefix":"10.1038","volume":"16","author":[{"given":"In\u00e9s","family":"G\u00f3mez-Acebo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Valero-Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Alonso-Molero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thal\u00eda","family":"Belmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Casta\u00f1o-Vinyals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina","family":"Romaguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Amiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Alguacil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"P\u00e9rez-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosana","family":"Burgui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Molina-Barcel\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paz","family":"Rodr\u00edguez-Cund\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manolis","family":"Kogevinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Poll\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trinidad","family":"Dierssen-Sotos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"41660_CR1","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1002\/ijc.35278","volume":"156","author":"AM Filho","year":"2025","unstructured":"Filho, A. M. et al. The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. Int. J. Cancer 156, 1336\u20131346 (2025).","journal-title":"Int. J. Cancer"},{"key":"41660_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103851","volume":"79","author":"L Liao","year":"2025","unstructured":"Liao, L. Inequality in breast cancer: Global statistics from 2022 to 2050. Breast Edinb. Scotl. 79, 103851 (2025).","journal-title":"Breast Edinb. Scotl."},{"key":"41660_CR3","unstructured":"Red Espa\u00f1ola de Registros de C\u00e1ncer (REDECAN). Estimaciones de La Incidencia Del C\u00e1ncer En Espa\u00f1a, 2025. https:\/\/redecan.org\/storage\/documentation\/442e1d1a-4040-4674-81cf-5e6a67af6458.pdf (2025)."},{"key":"41660_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-02108-4","volume":"10","author":"X Xiong","year":"2025","unstructured":"Xiong, X. et al. Breast cancer: Pathogenesis and treatments. Signal Transduct. Target. Ther. 10, 49 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"41660_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/biof.2146","volume":"51","author":"S Kumar","year":"2025","unstructured":"Kumar, S. & Ranga, A. Role of miRNAs in breast cancer development and progression: Current research. BioFactors Oxf. Engl. 51, e2146 (2025).","journal-title":"BioFactors Oxf. Engl."},{"key":"41660_CR6","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","volume":"321","author":"AG Waks","year":"2019","unstructured":"Waks, A. G. & Winer, E. P. Breast cancer treatment: A review. JAMA 321, 288\u2013300 (2019).","journal-title":"JAMA"},{"key":"41660_CR7","doi-asserted-by":"crossref","unstructured":"Howlader, N. et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J. Natl. Cancer Inst. 106, dju055 (2014).","DOI":"10.1093\/jnci\/dju055"},{"key":"41660_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101719","volume":"5","author":"Y-J Qi","year":"2024","unstructured":"Qi, Y.-J. et al. Radiomics in breast cancer: Current advances and future directions. Cell Rep. Med. 5, 101719 (2024).","journal-title":"Cell Rep. Med."},{"key":"41660_CR9","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s11864-024-01271-8","volume":"25","author":"G Spear","year":"2024","unstructured":"Spear, G., Lee, K., DePersia, A., Lienhoop, T. & Saha, P. Updates in breast cancer screening and diagnosis. Curr. Treat. Options Oncol. 25, 1451\u20131460 (2024).","journal-title":"Curr. Treat. Options Oncol."},{"key":"41660_CR10","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/jmri.28731","volume":"58","author":"MI Tsarouchi","year":"2023","unstructured":"Tsarouchi, M. I., Hoxhaj, A. & Mann, R. M. New approaches and recommendations for risk-adapted breast cancer screening. J. Magn. Reson. Imaging JMRI 58, 987\u20131010 (2023).","journal-title":"J. Magn. Reson. Imaging JMRI"},{"key":"41660_CR11","volume":"248","author":"A Azani","year":"2023","unstructured":"Azani, A. et al. MicroRNAs as biomarkers for early diagnosis, targeting and prognosis of prostate cancer. Pathology 248, 154618 (2023).","journal-title":"Pathology"},{"key":"41660_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: New dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"41660_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3892\/ijo.2024.5713","volume":"66","author":"WX Lee","year":"2025","unstructured":"Lee, W. X. et al. MicroRNAs and their role in breast cancer metabolism (Review). Int. J. Oncol. 66, 7 (2025).","journal-title":"Int. J. Oncol."},{"key":"41660_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2023.147761","volume":"888","author":"MM Khan","year":"2023","unstructured":"Khan, M. M., Sharma, V. & Serajuddin, M. Emerging role of miRNA in prostate cancer: A future era of diagnostic and therapeutics. Gene 888, 147761 (2023).","journal-title":"Gene"},{"key":"41660_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911502","volume":"23","author":"A Menon","year":"2022","unstructured":"Menon, A., Abd-Aziz, N., Khalid, K., Poh, C. L. & Naidu, R. miRNA: A promising therapeutic target in cancer. Int. J. Mol. Sci. 23, 11502 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"41660_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063140","volume":"25","author":"D Siniscalco","year":"2024","unstructured":"Siniscalco, D., Galderisi, U., Peluso, G. & Finicelli, M. Circulating microRNAs in cancer: A 5-Year update with a focus on breast and lung cancers. Int. J. Mol. Sci. 25, 3140 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"41660_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-022-06728-8","volume":"196","author":"THN Nguyen","year":"2022","unstructured":"Nguyen, T. H. N. et al. Panels of circulating microRNAs as potential diagnostic biomarkers for breast cancer: a systematic review and meta-analysis. Breast Cancer Res. Treat. 196, 1\u201315 (2022).","journal-title":"Breast Cancer Res. Treat."},{"key":"41660_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13058-015-0526-y","volume":"17","author":"E van Schooneveld","year":"2015","unstructured":"van Schooneveld, E. et al. Dysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management. Breast Cancer Res. BCR 17, 21 (2015).","journal-title":"Breast Cancer Res. BCR"},{"key":"41660_CR19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s40001-023-01471-2","volume":"28","author":"I G\u00f3mez-Acebo","year":"2023","unstructured":"G\u00f3mez-Acebo, I. et al. Circulating miRNAs signature on breast cancer: the MCC-Spain project. Eur. J. Med. Res. 28, 480 (2023).","journal-title":"Eur. J. Med. Res."},{"key":"41660_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22158290","volume":"22","author":"MG Davey","year":"2021","unstructured":"Davey, M. G., Davies, M., Lowery, A. J., Miller, N. & Kerin, M. J. The role of MicroRNA as clinical biomarkers for breast cancer surgery and treatment. Int. J. Mol. Sci. 22, 8290 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"41660_CR21","doi-asserted-by":"publisher","first-page":"8270","DOI":"10.3390\/ijms24098270","volume":"24","author":"A Garrido-Palacios","year":"2023","unstructured":"Garrido-Palacios, A. et al. MicroRNA dysregulation in early breast cancer diagnosis: A systematic review and meta-analysis. Int. J. Mol. Sci. 24, 8270 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"41660_CR22","doi-asserted-by":"publisher","first-page":"35188","DOI":"10.18632\/oncotarget.9072","volume":"7","author":"P Liu","year":"2016","unstructured":"Liu, P. et al. mir-101-3p is a key regulator of tumor metabolism in triple negative breast cancer targeting AMPK. Oncotarget 7, 35188\u201335198 (2016).","journal-title":"Oncotarget"},{"key":"41660_CR23","doi-asserted-by":"publisher","first-page":"8771","DOI":"10.7150\/thno.46142","volume":"10","author":"H-C Hong","year":"2020","unstructured":"Hong, H.-C. et al. A panel of eight microRNAs is a good predictive parameter for triple-negative breast cancer relapse. Theranostics 10, 8771\u20138789 (2020).","journal-title":"Theranostics"},{"key":"41660_CR24","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","volume":"26","author":"AS Coates","year":"2015","unstructured":"Coates, A. S. et al. Tailoring therapies\u2013improving the management of early breast cancer: St Gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 26, 1533\u20131546 (2015).","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"41660_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-031904","volume":"9","author":"J Alonso-Molero","year":"2019","unstructured":"Alonso-Molero, J. et al. Cohort profile: The MCC-Spain follow-up on colorectal, breast and prostate cancers: Study design and initial results. BMJ Open 9, e031904 (2019).","journal-title":"BMJ Open"},{"key":"41660_CR26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.gaceta.2014.12.003","volume":"29","author":"G Casta\u00f1o-Vinyals","year":"2015","unstructured":"Casta\u00f1o-Vinyals, G. et al. Population-based multicase-control study in common tumors in Spain (MCC-Spain): Rationale and study design. Gac. Sanit. 29, 308\u2013315 (2015).","journal-title":"Gac. Sanit."},{"key":"41660_CR27","doi-asserted-by":"publisher","first-page":"6325","DOI":"10.1007\/s11033-022-07440-y","volume":"49","author":"F Ahmadpour","year":"2022","unstructured":"Ahmadpour, F. et al. Methylation-mediated silencing of miR-125a-5p facilitates breast cancer progression by inducing autophagy. Mol. Biol. Rep. 49, 6325\u20136339 (2022).","journal-title":"Mol. Biol. Rep."},{"key":"41660_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713046","volume":"24","author":"M Almohaywi","year":"2023","unstructured":"Almohaywi, M. et al. Deregulated miRNA expression in triple-negative breast cancer of ancestral genomic-characterized Latina patients. Int. J. Mol. Sci. 24, 13046 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"41660_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260327","volume":"16","author":"A Amirfallah","year":"2021","unstructured":"Amirfallah, A. et al. Hsa-miR-21-3p associates with breast cancer patient survival and targets genes in tumor suppressive pathways. PLoS ONE 16, e0260327 (2021).","journal-title":"PLoS ONE"},{"key":"41660_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.752270","volume":"11","author":"A Aranza-Mart\u00ednez","year":"2021","unstructured":"Aranza-Mart\u00ednez, A. et al. Non-coding RNAs associated with radioresistance in triple-negative breast cancer. Front. Oncol. 11, 752270 (2021).","journal-title":"Front. Oncol."},{"key":"41660_CR31","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.10494","volume":"8","author":"Y Ashirbekov","year":"2020","unstructured":"Ashirbekov, Y. et al. Combination of circulating miR-145-5p\/miR-191-5p as biomarker for breast cancer detection. PeerJ 8, e10494 (2020).","journal-title":"PeerJ"},{"key":"41660_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2020.104076","volume":"127","author":"S Banerjee","year":"2020","unstructured":"Banerjee, S., Kalyani Yabalooru, S. R. & Karunagaran, D. Identification of mRNA and non-coding RNA hubs using network analysis in organ tropism regulated triple negative breast cancer metastasis. Comput. Biol. Med. 127, 104076 (2020).","journal-title":"Comput. Biol. Med."},{"key":"41660_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252413679","volume":"25","author":"S Bhattarai","year":"2024","unstructured":"Bhattarai, S. et al. Dysregulated miRNA expression and androgen receptor loss in racially distinct triple-negative breast cancer. Int. J. Mol. Sci. 25, 13679 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"41660_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087115","volume":"24","author":"L Bouz Mkabaah","year":"2023","unstructured":"Bouz Mkabaah, L. et al. Assessing the role of MicroRNAs in predicting breast cancer recurrence-a systematic review. Int. J. Mol. Sci. 24, 7115 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"41660_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ncrna.2020.12.001","volume":"6","author":"SB Bozkurt","year":"2021","unstructured":"Bozkurt, S. B., Ozturk, B., Kocak, N. & Unlu, A. Differences of time-dependent microRNA expressions in breast cancer cells. Non-coding RNA Res. 6, 15\u201322 (2021).","journal-title":"Non-coding RNA Res."},{"key":"41660_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072138","volume":"15","author":"P Cabello","year":"2023","unstructured":"Cabello, P. et al. miR-146a-5p promotes angiogenesis and confers trastuzumab resistance in HER2+ breast cancer. Cancers 15, 2138 (2023).","journal-title":"Cancers"},{"key":"41660_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168284","volume":"11","author":"JT-H Chang","year":"2016","unstructured":"Chang, J.T.-H., Wang, F., Chapin, W. & Huang, R. S. Identification of MicroRNAs as breast cancer prognosis markers through the Cancer Genome Atlas. PLoS ONE 11, e0168284 (2016).","journal-title":"PLoS ONE"},{"key":"41660_CR38","first-page":"302","volume":"49","author":"C Chen","year":"2019","unstructured":"Chen, C. et al. Clinical significance of let-7a-5p and miR-21-5p in patients with breast cancer. Ann. Clin. Lab. Sci. 49, 302\u2013308 (2019).","journal-title":"Ann. Clin. Lab. Sci."},{"key":"41660_CR39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s10020-023-00681-y","volume":"29","author":"Z-H Chen","year":"2023","unstructured":"Chen, Z.-H. et al. PAX5-miR-142 feedback loop promotes breast cancer proliferation by regulating DNMT1 and ZEB1. Mol. Med. (Camb. Mass.) 29, 89 (2023).","journal-title":"Mol. Med. (Camb. Mass.)"},{"key":"41660_CR40","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/1759-7714.14310","volume":"13","author":"H Cheng","year":"2022","unstructured":"Cheng, H., Kuang, S., Tan, L. & Sun, S. Circ_0001955 plays a carcinogenic role in breast cancer via positively regulating GLUT1 via decoying miR-1299. Thorac. Cancer 13, 913\u2013924 (2022).","journal-title":"Thorac. Cancer"},{"key":"41660_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-38886-0","volume":"13","author":"G Chiorino","year":"2023","unstructured":"Chiorino, G. et al. Plasma microRNA ratios associated with breast cancer detection in a nested case\u2013control study from a mammography screening cohort. Sci. Rep. 13, 12040 (2023).","journal-title":"Sci. Rep."},{"key":"41660_CR42","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11302-021-09824-4","volume":"18","author":"FC da Silva","year":"2022","unstructured":"da Silva, F. C. et al. Is the regulation by miRNAs of NTPDase1 and ecto-5\u2019-nucleotidase genes involved with the different profiles of breast cancer subtypes?. Purinergic Signal 18, 123\u2013133 (2022).","journal-title":"Purinergic Signal"},{"key":"41660_CR43","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4048\/jbc.2019.22.e19","volume":"22","author":"W Dai","year":"2019","unstructured":"Dai, W. et al. miR-148b-3p, miR-190b, and miR-429 regulate cell progression and act as potential biomarkers for breast cancer. J. Breast Cancer 22, 219\u2013236 (2019).","journal-title":"J. Breast Cancer"},{"key":"41660_CR44","doi-asserted-by":"crossref","unstructured":"Das, S. C. et al. Comprehensive bioinformatics and machine learning analyses for breast cancer staging using TCGA dataset. Brief. Bioinform. 26, bbae628 (2024).","DOI":"10.1093\/bib\/bbae628"},{"key":"41660_CR45","doi-asserted-by":"publisher","first-page":"8325","DOI":"10.1007\/s11033-022-07646-0","volume":"49","author":"N Dastmalchi","year":"2022","unstructured":"Dastmalchi, N. et al. The combined restoration of miR-424-5p and miR-142-3p effectively inhibits MCF-7 breast cancer cell line via modulating apoptosis, proliferation, colony formation, cell cycle and autophagy. Mol. Biol. Rep. 49, 8325\u20138335 (2022).","journal-title":"Mol. Biol. Rep."},{"key":"41660_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1028825","volume":"12","author":"S Di Cosimo","year":"2023","unstructured":"Di Cosimo, S. et al. End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO. Front. Oncol. 12, 1028825 (2023).","journal-title":"Front. Oncol."},{"key":"41660_CR47","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12032-024-02400-x","volume":"41","author":"L Dong","year":"2024","unstructured":"Dong, L. et al. Urinary extracellular vesicle-derived miR-126-3p predicts lymph node invasion in patients with high-risk prostate cancer. Med. Oncol. Northwood Lond. Engl. 41, 169 (2024).","journal-title":"Med. Oncol. Northwood Lond. Engl."},{"key":"41660_CR48","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2021.12585","volume":"21","author":"M Dong","year":"2021","unstructured":"Dong, M. et al. NCAPG upregulation mediated by four microRNAs combined with activation of the p53 signaling pathway is a predictor of poor prognosis in patients with breast cancer. Oncol. Lett. 21, 323 (2021).","journal-title":"Oncol. Lett."},{"key":"41660_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.627811","volume":"11","author":"D Escuin","year":"2021","unstructured":"Escuin, D. et al. Circulating microRNAs in early breast cancer patients and its association with lymph node metastases. Front. Oncol. 11, 627811 (2021).","journal-title":"Front. Oncol."},{"key":"41660_CR50","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1111\/1759-7714.15460","volume":"15","author":"JR Estupi\u00f1an-Jim\u00e9nez","year":"2024","unstructured":"Estupi\u00f1an-Jim\u00e9nez, J. R. et al. MicroRNA-1307-3p contributes to breast cancer progression through PRM2. Thorac. Cancer 15, 2298\u20132308 (2024).","journal-title":"Thorac. Cancer"},{"key":"41660_CR51","first-page":"322","volume":"16","author":"Y Fang","year":"2024","unstructured":"Fang, Y., Zhang, Q., Chen, Z., Guo, C. & Wu, J. Clinical significance and immune characteristics analysis of miR-221-3p and its key target genes related to epithelial-mesenchymal transition in breast cancer. Aging 16, 322\u2013347 (2024).","journal-title":"Aging"},{"key":"41660_CR52","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1038\/s41598-021-82286-1","volume":"11","author":"A Fontana","year":"2021","unstructured":"Fontana, A. et al. Combined analysis of miR-200 family and its significance for breast cancer. Sci. Rep. 11, 2980 (2021).","journal-title":"Sci. Rep."},{"key":"41660_CR53","doi-asserted-by":"publisher","first-page":"6780","DOI":"10.18632\/aging.204253","volume":"14","author":"H Fu","year":"2022","unstructured":"Fu, H., Li, K., Wang, S. & Li, Y. High expression of CCNB1 driven by ncRNAs is associated with a poor prognosis and tumor immune infiltration in breast cancer. Aging 14, 6780\u20136795 (2022).","journal-title":"Aging"},{"key":"41660_CR54","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3892\/ol.2016.4582","volume":"12","author":"L Fu","year":"2016","unstructured":"Fu, L. et al. Serum expression levels of microRNA-382-3p, -598-3p, -1246 and -184 in breast cancer patients. Oncol. Lett. 12, 269\u2013274 (2016).","journal-title":"Oncol. Lett."},{"key":"41660_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11080816","volume":"11","author":"P Fuso","year":"2021","unstructured":"Fuso, P. et al. Let-7a-5p, miR-100-5p, miR-101-3p, and miR-199a-3p hyperexpression as potential predictive biomarkers in early breast cancer patients. J. Pers. Med. 11, 816 (2021).","journal-title":"J. Pers. Med."},{"key":"41660_CR56","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.3390\/cancers14071851","volume":"14","author":"M Gallo","year":"2022","unstructured":"Gallo, M. et al. The EGFR signaling modulates in mesenchymal stem cells the expression of miRNAs involved in the interaction with breast cancer cells. Cancers 14, 1851 (2022).","journal-title":"Cancers"},{"key":"41660_CR57","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41598-019-56571-z","volume":"10","author":"X-H Gao","year":"2020","unstructured":"Gao, X.-H. et al. MicroRNA-96-5p represses breast cancer proliferation and invasion through Wnt\/\u03b2-catenin signaling via targeting CTNND1. Sci. Rep. 10, 44 (2020).","journal-title":"Sci. Rep."},{"key":"41660_CR58","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.4103\/jcrt.JCRT_1111_19","volume":"16","author":"N Garc\u00eda-Magallanes","year":"2020","unstructured":"Garc\u00eda-Magallanes, N. et al. Underexpression of circulating miR-145-5p and miR-133a-3p are associated with breast cancer and immunohistochemical markers. J. Cancer Res. Ther. 16, 1223\u20131228 (2020).","journal-title":"J. Cancer Res. Ther."},{"key":"41660_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.109979","volume":"83","author":"Z Hamurcu","year":"2021","unstructured":"Hamurcu, Z. et al. MicroRNA profiling identifies Forkhead box transcription factor M1 (FOXM1) regulated miR-186 and miR-200b alterations in triple negative breast cancer. Cell. Signal. 83, 109979 (2021).","journal-title":"Cell. Signal."},{"key":"41660_CR60","doi-asserted-by":"publisher","first-page":"6993","DOI":"10.18632\/aging.204887","volume":"15","author":"H Hao","year":"2023","unstructured":"Hao, H. et al. miRNA-186-5p inhibits migration, invasion and proliferation of breast cancer cells by targeting SBEM. Aging 15, 6993\u20137007 (2023).","journal-title":"Aging"},{"key":"41660_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e07919","volume":"7","author":"K Hashimoto","year":"2021","unstructured":"Hashimoto, K., Inada, M., Yamamoto, Y. & Ochiya, T. Preliminary evaluation of miR-1307-3p in human serum for detection of 13 types of solid cancer using microRNA chip. Heliyon 7, e07919 (2021).","journal-title":"Heliyon"},{"key":"41660_CR62","doi-asserted-by":"crossref","unstructured":"Hosseinpour, Z., Rezaei Tavirani, M. & Akbari, M. E. Stage Analysis of Breast Cancer Metabolomics: A System Biology Approach. Asian Pac. J. Cancer Prev. APJCP 24, 1571\u20131582 (2023).","DOI":"10.31557\/APJCP.2023.24.5.1571"},{"key":"41660_CR63","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1007\/s12282-024-01619-w","volume":"31","author":"Z Hu","year":"2024","unstructured":"Hu, Z. et al. Identification and validation of screening models for breast cancer with 3 serum miRNAs in an 11,349 samples mixed cohort. Breast Cancer 31, 1046\u20131058 (2024).","journal-title":"Breast Cancer"},{"key":"41660_CR64","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22116121","volume":"22","author":"MM Itani","year":"2021","unstructured":"Itani, M. M. et al. A signature of four circulating microRNAs as potential biomarkers for diagnosing early-stage breast cancer. Int. J. Mol. Sci. 22, 6121 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"41660_CR65","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3892\/ijo.2020.5150","volume":"58","author":"H Jia","year":"2021","unstructured":"Jia, H., Wu, D., Zhang, Z. & Li, S. Regulatory effect of the MAFG-AS1\/miR-150-5p\/MYB axis on the proliferation and migration of breast cancer cells. Int. J. Oncol. 58, 33\u201344 (2021).","journal-title":"Int. J. Oncol."},{"key":"41660_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2024.1482927","volume":"15","author":"Y Jing","year":"2024","unstructured":"Jing, Y. et al. Diagnostic value of 5 miRNAs combined detection for breast cancer. Front. Genet. 15, 1482927 (2024).","journal-title":"Front. Genet."},{"key":"41660_CR67","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3892\/ol.2024.14291","volume":"27","author":"M Kim","year":"2024","unstructured":"Kim, M. et al. Exploring miRNA-target gene profiles associated with drug resistance in patients with breast cancer receiving neoadjuvant chemotherapy. Oncol. Lett. 27, 158 (2024).","journal-title":"Oncol. Lett."},{"key":"41660_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310785","volume":"24","author":"TT Komoto","year":"2023","unstructured":"Komoto, T. T. et al. Exploring the therapeutic potential of trans-chalcone: Modulation of microRNAs linked to breast cancer progression in MCF-7 cells. Int. J. Mol. Sci. 24, 10785 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"41660_CR69","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.3390\/cells13221884","volume":"13","author":"J Kujala","year":"2024","unstructured":"Kujala, J. et al. Circulating micro-RNAs predict the risk of recurrence in triple-negative breast cancer. Cells 13, 1884 (2024).","journal-title":"Cells"},{"key":"41660_CR70","doi-asserted-by":"crossref","unstructured":"Lee, S. H. & Brianna. Association of microRNA-21 expression with breast cancer subtypes and its potential as an early biomarker. Pathol. - Res. Pract. 254, 155073 (2024).","DOI":"10.1016\/j.prp.2023.155073"},{"key":"41660_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03537-w","volume":"9","author":"H Li","year":"2018","unstructured":"Li, H. et al. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Nat. Commun. 9, 1614 (2018).","journal-title":"Nat. Commun."},{"key":"41660_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216995","volume":"597","author":"S-Y Li","year":"2024","unstructured":"Li, S.-Y. et al. Deciphering the TCF19\/miR-199a-5p\/SP1\/LOXL2 pathway: Implications for breast cancer metastasis and epithelial-mesenchymal transition. Cancer Lett. 597, 216995 (2024).","journal-title":"Cancer Lett."},{"key":"41660_CR73","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.bbrc.2018.08.172","volume":"504","author":"Y Li","year":"2018","unstructured":"Li, Y., Wang, Y., Fan, H., Zhang, Z. & Li, N. miR-125b-5p inhibits breast cancer cell proliferation, migration and invasion by targeting KIAA1522. Biochem. Biophys. Res. Commun. 504, 277\u2013282 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"41660_CR74","doi-asserted-by":"publisher","first-page":"355","DOI":"10.4048\/jbc.2020.23.e47","volume":"23","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. MiR-183-5p promotes proliferation, metastasis and angiogenesis in breast cancer cells through negatively regulating four and a half LIM protein 1. J. Breast Cancer 23, 355\u2013372 (2020).","journal-title":"J. Breast Cancer"},{"key":"41660_CR75","doi-asserted-by":"publisher","first-page":"7813083","DOI":"10.1155\/2024\/7813083","volume":"2024","author":"W Liang","year":"2024","unstructured":"Liang, W. et al. Inhibition of lymphangiogenesis: A protective role of microRNA 146a\u20135p in breast cancer. Breast J. 2024, 7813083 (2024).","journal-title":"Breast J."},{"key":"41660_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58101494","volume":"58","author":"LA Lisencu","year":"2022","unstructured":"Lisencu, L. A. et al. The role of miR-375-3p, miR-210-3p and Let-7e-5p in the pathological response of breast cancer patients to neoadjuvant therapy. Medicina 58, 1494 (2022).","journal-title":"Medicina"},{"key":"41660_CR77","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.822721","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu, J., Xiao, S., Chen, J., Lou, W. & Chen, X. A comprehensive analysis for expression, diagnosis, and prognosis of m5C regulator in breast cancer and its ncRNA-mRNA regulatory mechanism. Front. Genet. 13, 822721 (2022).","journal-title":"Front. Genet."},{"key":"41660_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01466-7","volume":"20","author":"W Lou","year":"2020","unstructured":"Lou, W., Ding, B., Wang, S. & Fu, P. Overexpression of GPX3, a potential biomarker for diagnosis and prognosis of breast cancer, inhibits progression of breast cancer cells in vitro. Cancer Cell Int. 20, 378 (2020).","journal-title":"Cancer Cell Int."},{"key":"41660_CR79","first-page":"521","volume":"56","author":"Z Lu","year":"2025","unstructured":"Lu, Z. et al. Expressions of miR-27a-3p mRNA and YAP1 mRNA in breast cancer and the relationship with clinicopathology and survival prognosis. Sichuan Da Xue Xue Bao Yi Xue Ban 56, 521\u2013527 (2025).","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"41660_CR80","doi-asserted-by":"crossref","unstructured":"Luo, Q., Tian, Y., Qu, G., Kun-Huang & Luo, S. Functional mechanism and clinical implications of miR-141 in human cancers. Cell. Signal. 95, 110354 (2022).","DOI":"10.1016\/j.cellsig.2022.110354"},{"key":"41660_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.125295","volume":"244","author":"J Ma","year":"2023","unstructured":"Ma, J. et al. CircEGFR reduces the sensitivity of pirarubicin and regulates the malignant progression of triple-negative breast cancer via the miR-1299\/EGFR axis. Int. J. Biol. Macromol. 244, 125295 (2023).","journal-title":"Int. J. Biol. Macromol."},{"key":"41660_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/s11658-021-00288-3","volume":"26","author":"S Ma","year":"2021","unstructured":"Ma, S. et al. MiR-26b-5p inhibits cell proliferation and EMT by targeting MYCBP in triple-negative breast cancer. Cell. Mol. Biol. Lett. 26, 52 (2021).","journal-title":"Cell. Mol. Biol. Lett."},{"key":"41660_CR83","doi-asserted-by":"publisher","DOI":"10.1007\/s10528-025-11057-8","author":"A Mardi","year":"2025","unstructured":"Mardi, A., Ghovahi, A., Abbasvandi, F. & Amani, D. Experimental validation of miR-4443, miR-572, and miR-150\u20135p in serum and tissue of breast cancer patients as a potential diagnostic biomarker: A study based on bioinformatics prediction. Biochem. Genet. https:\/\/doi.org\/10.1007\/s10528-025-11057-8 (2025).","journal-title":"Biochem. Genet."},{"key":"41660_CR84","doi-asserted-by":"publisher","DOI":"10.1007\/s12041-021-01265-7","volume":"100","author":"M Maryam","year":"2021","unstructured":"Maryam, M., Naemi, M. & Hasani, S. S. A comprehensive review on oncogenic miRNAs in breast cancer. J. Genet. 100, 15 (2021).","journal-title":"J. Genet."},{"key":"41660_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinsp.2022.100155","volume":"78","author":"DCC Mendes","year":"2023","unstructured":"Mendes, D. C. C. et al. Could be FOXO3a, miR-96-5p and miR-182-5p useful for Brazilian women with luminal A and triple negative breast cancers prognosis and target therapy?. Clinics 78, 100155 (2023).","journal-title":"Clinics"},{"key":"41660_CR86","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.canlet.2021.07.001","volume":"520","author":"M Minini","year":"2021","unstructured":"Minini, M. et al. miR-125a-5p impairs the metastatic potential in breast cancer via IP6K1 targeting. Cancer Lett. 520, 48\u201356 (2021).","journal-title":"Cancer Lett."},{"key":"41660_CR87","first-page":"2330","volume":"5","author":"R Murria","year":"2015","unstructured":"Murria, R. et al. Immunohistochemical, genetic and epigenetic profiles of hereditary and triple negative breast cancers. Relevance in personalized medicine. Am. J. Cancer Res. 5, 2330\u20132343 (2015).","journal-title":"Am. J. Cancer Res."},{"key":"41660_CR88","doi-asserted-by":"crossref","unstructured":"Naser Al Deen, N. et al. Over-expression of miR-183\u20135p or miR-492 triggers invasion and proliferation and loss of polarity in non-neoplastic breast epithelium. Sci. Rep. 12, 21974 (2022).","DOI":"10.1038\/s41598-022-25663-8"},{"key":"41660_CR89","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3320","volume":"23","author":"Z Nashtahosseini","year":"2021","unstructured":"Nashtahosseini, Z., Aghamaali, M. R., Sadeghi, F., Heydari, N. & Parsian, H. Circulating status of microRNAs 660\u20135p and 210\u20133p in breast cancer patients. J. Gene Med. 23, e3320 (2021).","journal-title":"J. Gene Med."},{"key":"41660_CR90","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12864-024-10174-9","volume":"25","author":"J Pei","year":"2024","unstructured":"Pei, J. et al. Integrated analysis reveals FLI1 regulates the tumor immune microenvironment via its cell-type-specific expression and transcriptional regulation of distinct target genes of immune cells in breast cancer. BMC Genomics 25, 250 (2024).","journal-title":"BMC Genomics"},{"key":"41660_CR91","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10549-025-07723-5","volume":"212","author":"E Perez-Moreno","year":"2025","unstructured":"Perez-Moreno, E. et al. Suppression of breast cancer metastatic behavior by microRNAs targeting EMT transcription factors. A relevant participation of miR-196a-5p and miR-22\u20133p in ZEB1 expression. Breast Cancer Res. Treat. 212, 277\u2013290 (2025).","journal-title":"Breast Cancer Res. Treat."},{"key":"41660_CR92","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00432-018-2689-2","volume":"144","author":"D Piasecka","year":"2018","unstructured":"Piasecka, D., Braun, M., Kordek, R., Sadej, R. & Romanska, H. MicroRNAs in regulation of triple-negative breast cancer progression. J. Cancer Res. Clin. Oncol. 144, 1401\u20131411 (2018).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"41660_CR93","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10549-024-07299-6","volume":"206","author":"S Pizzamiglio","year":"2024","unstructured":"Pizzamiglio, S. et al. Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: An exploratory analysis from NeoALTTO. Breast Cancer Res. Treat. 206, 285\u2013294 (2024).","journal-title":"Breast Cancer Res. Treat."},{"key":"41660_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2021.104601","volume":"135","author":"D Rajarajan","year":"2021","unstructured":"Rajarajan, D., Kaur, B., Penta, D., Natesh, J. & Meeran, S. M. MiR-145-5p as a predictive biomarker for breast cancer stemness by computational clinical investigation. Comput. Biol. Med. 135, 104601 (2021).","journal-title":"Comput. Biol. Med."},{"key":"41660_CR95","volume":"17","author":"S Razi","year":"2023","unstructured":"Razi, S., Mozdarani, H. & Behzadi Andouhjerdi, R. Evaluation of the potential diagnostic role of the Lnc-MIAT, miR-29a-3p, and FOXO3a ceRNA networks as noninvasive circulatory bioindicator in ductal carcinoma breast cancer. Breast Cancer: Basic Clin. Res. 17, 11782234231184378 (2023).","journal-title":"Breast Cancer: Basic Clin. Res."},{"key":"41660_CR96","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-68758-0","volume":"14","author":"GM Salum","year":"2024","unstructured":"Salum, G. M. et al. Evaluation of tumorigenesis-related miRNAs in breast cancer in Egyptian women: A retrospective, exploratory analysis. Sci. Rep. 14, 29757 (2024).","journal-title":"Sci. Rep."},{"key":"41660_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11101955","volume":"11","author":"R S\u00e1nchez-S\u00e1nchez","year":"2022","unstructured":"S\u00e1nchez-S\u00e1nchez, R. et al. MicroRNA-4732-3p is dysregulated in breast cancer patients with cardiotoxicity, and its therapeutic delivery protects the heart from doxorubicin-induced oxidative stress in rats. Antioxidants 11, 1955 (2022).","journal-title":"Antioxidants"},{"key":"41660_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241612762","volume":"24","author":"MdeFM Santana","year":"2023","unstructured":"Santana, MdeFM. et al. Increased expression of miR-223-3p and miR-375-3p and anti-inflammatory activity in HDL of newly diagnosed women in advanced stages of breast cancer. Int. J. Mol. Sci. 24, 12762 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"41660_CR99","first-page":"1099","volume":"37","author":"X Shao","year":"2022","unstructured":"Shao, X. et al. Hsa-miR-221-3p promotes proliferation and migration in HER2-positive breast cancer cells by targeting LASS2 and MBD2. Histol. Histopathol. 37, 1099\u20131112 (2022).","journal-title":"Histol. Histopathol."},{"key":"41660_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120727","volume":"304","author":"P Sharma","year":"2022","unstructured":"Sharma, P. et al. HMGB3 inhibition by miR-142-3p\/sh-RNA modulates autophagy and induces apoptosis via ROS accumulation and mitochondrial dysfunction and reduces the tumorigenic potential of human breast cancer cells. Life Sci. 304, 120727 (2022).","journal-title":"Life Sci."},{"key":"41660_CR101","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/1759-7714.14803","volume":"14","author":"B-J Shen","year":"2023","unstructured":"Shen, B.-J., Yang, Y.-F. & Zhang, X.-X. Hsa_circ_0001925 promotes malignant progression in triple-negative breast cancer via miR-1299\/YY1 axis. Thorac. Cancer 14, 746\u2013757 (2023).","journal-title":"Thorac. Cancer"},{"key":"41660_CR102","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/s41388-024-02950-4","volume":"43","author":"H Song","year":"2024","unstructured":"Song, H. et al. Novel exosomal circEGFR facilitates triple negative breast cancer autophagy via promoting TFEB nuclear trafficking and modulating miR-224-5p\/ATG13\/ULK1 feedback loop. Oncogene 43, 821\u2013836 (2024).","journal-title":"Oncogene"},{"key":"41660_CR103","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.7150\/jca.46898","volume":"11","author":"Y Song","year":"2020","unstructured":"Song, Y. et al. EPAS1 targeting by miR-152-3p in Paclitaxel-resistant breast cancer. J. Cancer 11, 5822\u20135830 (2020).","journal-title":"J. Cancer"},{"key":"41660_CR104","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13058-025-02029-2","volume":"27","author":"GB Spychalski","year":"2025","unstructured":"Spychalski, G. B. et al. miRNA panel from HER2+ and CD24+ plasma extracellular vesicle subpopulations as biomarkers of early-stage breast cancer. Breast Cancer Res. 27, 90 (2025).","journal-title":"Breast Cancer Res."},{"key":"41660_CR105","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12915-025-02133-x","volume":"23","author":"OE Sumer","year":"2025","unstructured":"Sumer, O. E. et al. Selective arm-usage of pre-miR-1307 dysregulates angiogenesis and affects breast cancer aggressiveness. BMC Biol. 23, 25 (2025).","journal-title":"BMC Biol."},{"key":"41660_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118435","volume":"261","author":"D Sun","year":"2020","unstructured":"Sun, D., Luo, X., Ma, L., Wang, Y. & Zhang, F. Identifying of miR-98-5p\/IGF1 axis contributes breast cancer progression using comprehensive bioinformatic analyses methods and experiments validation. Life Sci. 261, 118435 (2020).","journal-title":"Life Sci."},{"key":"41660_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.857714","volume":"12","author":"H Sun","year":"2022","unstructured":"Sun, H. et al. miR-139-5p was identified as biomarker of different molecular subtypes of breast carcinoma. Front. Oncol. 12, 857714 (2022).","journal-title":"Front. Oncol."},{"key":"41660_CR108","volume":"262","author":"RU Syed","year":"2024","unstructured":"Syed, R. U. et al. MicroRNA-21 (miR-21) in breast cancer: From apoptosis dysregulation to therapeutic opportunities. Pathology 262, 155572 (2024).","journal-title":"Pathology"},{"key":"41660_CR109","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133424","volume":"15","author":"P Tiberio","year":"2023","unstructured":"Tiberio, P. et al. Unlocking the potential of circulating miRNAs in the breast cancer neoadjuvant setting: A systematic review and meta-analysis. Cancers 15, 3424 (2023).","journal-title":"Cancers"},{"key":"41660_CR110","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216400","volume":"14","author":"K Uhr","year":"2019","unstructured":"Uhr, K. et al. MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines. PLoS ONE 14, e0216400 (2019).","journal-title":"PLoS ONE"},{"key":"41660_CR111","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3390\/jcm12010322","volume":"12","author":"S Wang","year":"2022","unstructured":"Wang, S. et al. Identification of three circulating MicroRNAs in plasma as clinical biomarkers for breast cancer detection. J. Clin. Med. 12, 322 (2022).","journal-title":"J. Clin. Med."},{"key":"41660_CR112","first-page":"7146338","volume":"2022","author":"T Wang","year":"2022","unstructured":"Wang, T. et al. Bioinformatics analysis reveals the related role of miR-511-5p in the progression of breast cancer. J. Healthc. Eng. 2022, 7146338 (2022).","journal-title":"J. Healthc. Eng."},{"key":"41660_CR113","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1166666","volume":"13","author":"Z Wang","year":"2023","unstructured":"Wang, Z. et al. miR-186-ANXA9 signaling inhibits tumorigenesis in breast cancer. Front. Oncol. 13, 1166666 (2023).","journal-title":"Front. Oncol."},{"key":"41660_CR114","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-5192","volume":"8","author":"X Wu","year":"2020","unstructured":"Wu, X., Chen, H., Wu, M., Peng, S. & Zhang, L. Downregulation of miR-182-5p inhibits the proliferation and invasion of triple-negative breast cancer cells through regulating TLR4\/NF-\u03baB pathway activity by targeting FBXW7. Ann. Transl. Med. 8, 995 (2020).","journal-title":"Ann. Transl. Med."},{"key":"41660_CR115","first-page":"301","volume":"19","author":"X Wu","year":"2020","unstructured":"Wu, X., Ding, M. & Lin, J. Three-microRNA expression signature predicts survival in triple-negative breast cancer. Oncol. Lett. 19, 301\u2013308 (2020).","journal-title":"Oncol. Lett."},{"key":"41660_CR116","doi-asserted-by":"publisher","DOI":"10.21037\/atm-22-97","volume":"10","author":"M Yang","year":"2022","unstructured":"Yang, M. et al. MiR-93-5p regulates tumorigenesis and tumor immunity by targeting PD-L1\/CCND1 in breast cancer. Ann. Transl. Med. 10, 203 (2022).","journal-title":"Ann. Transl. Med."},{"key":"41660_CR117","first-page":"695","volume":"15","author":"J Yu","year":"2023","unstructured":"Yu, J. et al. Hsa_circ_0007823 overexpression suppresses the progression of triple-negative breast cancer via regulating miR-182-5p-FOXO1 axis. Breast Cancer Dove Med. Press 15, 695\u2013708 (2023).","journal-title":"Breast Cancer Dove Med. Press"},{"key":"41660_CR118","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/CM9.0000000000002700","volume":"137","author":"X Yu","year":"2024","unstructured":"Yu, X. et al. Promotion effect of FOXCUT as a microRNA sponge for miR-24-3p on progression in triple-negative breast cancer through the p38 MAPK signaling pathway. Chin. Med. J. (Engl.) 137, 105\u2013114 (2024).","journal-title":"Chin. Med. J. (Engl.)"},{"key":"41660_CR119","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.3390\/cancers15174329","volume":"15","author":"P Zayakin","year":"2023","unstructured":"Zayakin, P. et al. Extracellular vesicles-a source of RNA biomarkers for the detection of breast cancer in liquid biopsies. Cancers 15, 4329 (2023).","journal-title":"Cancers"},{"key":"41660_CR120","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2010-11-3-r25","volume":"11","author":"MD Robinson","year":"2010","unstructured":"Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).","journal-title":"Genome Biol."},{"key":"41660_CR121","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B Stat. Methodol. 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Ser. B Stat. Methodol."},{"key":"41660_CR122","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","volume":"58","author":"R Tibshirani","year":"1996","unstructured":"Tibshirani, R. Regression shrinkage and selection via the lasso. J. R. Stat. Soc. Ser. B Methodol. 58, 267\u2013288 (1996).","journal-title":"J. R. Stat. Soc. Ser. B Methodol."},{"key":"41660_CR123","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-01373-9","volume":"15","author":"I G\u00f3mez-Acebo","year":"2025","unstructured":"G\u00f3mez-Acebo, I. et al. Role of circulating MicroRNAs in prostate cancer diagnosis and risk stratification in the MCC Spain study. Sci. Rep. 15, 17517 (2025).","journal-title":"Sci. Rep."},{"key":"41660_CR124","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/cas.12880","volume":"107","author":"A Shimomura","year":"2016","unstructured":"Shimomura, A. et al. Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci. 107, 326\u2013334 (2016).","journal-title":"Cancer Sci."},{"key":"41660_CR125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013735","volume":"5","author":"H Zhao","year":"2010","unstructured":"Zhao, H. et al. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE 5, e13735 (2010).","journal-title":"PLoS ONE"},{"key":"41660_CR126","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-024-09352-5","volume":"51","author":"S Babadag","year":"2024","unstructured":"Babadag, S., Altundag-Erdogan, \u00d6., Akkaya-Ulum, Y. Z. & \u00c7elebi-Saltik, B. The role of telocytes and miR-21-5p in tumorigenicity and metastasis of breast cancer stem cells. Mol. Biol. Rep. 51, 395 (2024).","journal-title":"Mol. Biol. Rep."},{"key":"41660_CR127","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.12147","volume":"9","author":"M Liu","year":"2021","unstructured":"Liu, M. et al. Exosomal hsa-miR-21-5p is a biomarker for breast cancer diagnosis. PeerJ 9, e12147 (2021).","journal-title":"PeerJ"},{"key":"41660_CR128","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4048\/jbc.2018.21.e56","volume":"21","author":"X Yu","year":"2018","unstructured":"Yu, X. et al. Identification and validation of circulating microRNA signatures for breast cancer early detection based on large scale tissue-derived data. J. Breast Cancer 21, 363\u2013370 (2018).","journal-title":"J. Breast Cancer"},{"key":"41660_CR129","doi-asserted-by":"publisher","first-page":"4763","DOI":"10.1007\/s13277-015-3126-7","volume":"36","author":"H Zhao","year":"2015","unstructured":"Zhao, H. et al. Genetic analysis and preliminary function study of miR-423 in breast cancer. Tumor Biol 36, 4763\u20134771 (2015).","journal-title":"Tumor Biol"},{"key":"41660_CR130","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3230","volume":"22","author":"S Sun","year":"2020","unstructured":"Sun, S., Ma, J., Xie, P., Wu, Z. & Tian, X. Hypoxia-responsive miR-141\u20133p is involved in the progression of breast cancer via mediating the HMGB1\/HIF-1\u03b1 signaling pathway. J. Gene Med. 22, e3230 (2020).","journal-title":"J. Gene Med."},{"key":"41660_CR131","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21228589","volume":"21","author":"M Taha","year":"2020","unstructured":"Taha, M., Mitwally, N., Soliman, A. S. & Yousef, E. Potential diagnostic and prognostic utility of miR-141, miR-181b1, and miR-23b in breast cancer. Int. J. Mol. Sci. 21, 8589 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"41660_CR132","doi-asserted-by":"publisher","first-page":"153303382090582","DOI":"10.1177\/1533033820905824","volume":"19","author":"M Zhao","year":"2020","unstructured":"Zhao, M. et al. miR-331-3p suppresses cell proliferation in TNBC cells by downregulating NRP2. Technol. Cancer Res. Treat. 19, 1533033820905824 (2020).","journal-title":"Technol. Cancer Res. Treat."},{"key":"41660_CR133","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/ijc.30142","volume":"139","author":"VD Haakensen","year":"2016","unstructured":"Haakensen, V. D. et al. Subtype-specific micro-RNA expression signatures in breast cancer progression. Int. J. Cancer 139, 1117\u20131128 (2016).","journal-title":"Int. J. Cancer"},{"key":"41660_CR134","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-00871-y","volume":"15","author":"F Turkoglu","year":"2024","unstructured":"Turkoglu, F., Calisir, A. & Ozturk, B. Clinical importance of serum miRNA levels in breast cancer patients. Discov. Oncol. 15, 19 (2024).","journal-title":"Discov. Oncol."},{"key":"41660_CR135","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jss.2020.08.051","volume":"258","author":"T Wu","year":"2021","unstructured":"Wu, T. et al. Sevoflurane suppresses the migration, invasion, and epithelial-mesenchymal transition of breast cancer cells through the miR-139-5p\/ARF6 axis. J. Surg. Res. 258, 314\u2013323 (2021).","journal-title":"J. Surg. Res."},{"key":"41660_CR136","doi-asserted-by":"publisher","first-page":"4772","DOI":"10.1002\/jcb.29700","volume":"121","author":"J Fang","year":"2020","unstructured":"Fang, J. et al. LncRNA TTN-AS1 facilitates proliferation, invasion, and epithelial-mesenchymal transition of breast cancer cells by regulating miR-139-5p\/ZEB1 axis. J. Cell. Biochem. 121, 4772\u20134784 (2020).","journal-title":"J. Cell. Biochem."},{"key":"41660_CR137","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1158\/0008-5472.CAN-16-3105","volume":"78","author":"M Pajic","year":"2018","unstructured":"Pajic, M. et al. miR-139-5p modulates radiotherapy resistance in breast cancer by repressing multiple gene networks of DNA repair and ROS defense. Cancer Res. 78, 501\u2013515 (2018).","journal-title":"Cancer Res."},{"key":"41660_CR138","doi-asserted-by":"publisher","DOI":"10.3390\/ph13070144","volume":"13","author":"R Harati","year":"2020","unstructured":"Harati, R., Mohammad, M. G., Tlili, A., El-Awady, R. A. & Hamoudi, R. Loss of miR-101-3p promotes transmigration of metastatic breast cancer cells through the brain endothelium by inducing COX-2\/MMP1 signaling. Pharmaceuticals 13, 144 (2020).","journal-title":"Pharmaceuticals"},{"key":"41660_CR139","doi-asserted-by":"publisher","first-page":"9599","DOI":"10.2147\/OTT.S264600","volume":"13","author":"H Jiang","year":"2020","unstructured":"Jiang, H. et al. MiR-101-3p and Syn-Cal14.1a synergy in suppressing EZH2-induced progression of breast cancer. OncoTargets Ther. 13, 9599\u20139609 (2020).","journal-title":"OncoTargets Ther."},{"key":"41660_CR140","first-page":"10262","volume":"13","author":"J Shao","year":"2021","unstructured":"Shao, J., Zhang, Q., Wang, P. & Wang, Z. LncRNA MALAT1 promotes breast cancer progression by sponging miR101-3p to mediate mTOR\/PKM2 signal transmission. Am. J. Transl. Res. 13, 10262\u201310275 (2021).","journal-title":"Am. J. Transl. Res."},{"key":"41660_CR141","doi-asserted-by":"publisher","first-page":"11477","DOI":"10.2147\/CMAR.S265579","volume":"12","author":"J Wang","year":"2020","unstructured":"Wang, J., Huang, K., Shi, L., Zhang, Q. & Zhang, S. CircPVT1 promoted the progression of breast cancer by regulating MiR-29a-3p-mediated AGR2-HIF-1\u03b1 pathway. Cancer Manag. Res. 12, 11477\u201311490 (2020).","journal-title":"Cancer Manag. Res."},{"key":"41660_CR142","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.117179","volume":"244","author":"B Zhao","year":"2020","unstructured":"Zhao, B., Song, X. & Guan, H. CircACAP2 promotes breast cancer proliferation and metastasis by targeting miR-29a\/b-3p-COL5A1 axis. Life Sci. 244, 117179 (2020).","journal-title":"Life Sci."},{"key":"41660_CR143","doi-asserted-by":"publisher","first-page":"924","DOI":"10.18632\/oncoscience.275","volume":"2","author":"H Tashkandi","year":"2015","unstructured":"Tashkandi, H., Shah, N., Patel, Y. & Chen, H. Identification of new miRNA biomarkers associated with HER2-positive breast cancers. Oncoscience 2, 924\u2013929 (2015).","journal-title":"Oncoscience"},{"key":"41660_CR144","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2018.8589","author":"G Wei","year":"2018","unstructured":"Wei, G. et al. Expression of miR-146a-5p in breast cancer and its role in proliferation of breast cancer cells. Oncol. Lett. https:\/\/doi.org\/10.3892\/ol.2018.8589 (2018).","journal-title":"Oncol. Lett."},{"key":"41660_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20477-0","volume":"12","author":"L Jing","year":"2022","unstructured":"Jing, L., Lan, L., Mingxin, Z. & Zhaofeng, Z. METTL3\/LINC00662\/miR-186-5p feedback loop regulates docetaxel resistance in triple negative breast cancer. Sci. Rep. 12, 16715 (2022).","journal-title":"Sci. Rep."},{"key":"41660_CR146","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03684-x","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. Up-regulated circBACH2 contributes to cell proliferation, invasion, and migration of triple-negative breast cancer. Cell Death Dis. 12, 412 (2021).","journal-title":"Cell Death Dis."},{"key":"41660_CR147","doi-asserted-by":"publisher","first-page":"16043","DOI":"10.1002\/jcp.28263","volume":"234","author":"B Mansoori","year":"2019","unstructured":"Mansoori, B. et al. miR-142-3p is a tumor suppressor that inhibits estrogen receptor expression in ER-positive breast cancer. J. Cell. Physiol. 234, 16043\u201316053 (2019).","journal-title":"J. Cell. Physiol."},{"key":"41660_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153458","volume":"222","author":"K Zhang","year":"2021","unstructured":"Zhang, K. et al. A two-miRNA signature of upregulated miR-185-5p and miR-362-5p as a blood biomarker for breast cancer. Pathol. Res. Pract. 222, 153458 (2021).","journal-title":"Pathol. Res. Pract."},{"key":"41660_CR149","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.31557\/APJCP.2021.22.5.1375","volume":"22","author":"AR Jusoh","year":"2021","unstructured":"Jusoh, A. R. et al. Plasma circulating Mirnas profiling for identification of potential breast cancer early detection biomarkers. Asian Pac. J. Cancer Prev. 22, 1375\u20131381 (2021).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"41660_CR150","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119431","volume":"276","author":"B Mansoori","year":"2021","unstructured":"Mansoori, B. et al. MiR-142-3p targets HMGA2 and suppresses breast cancer malignancy. Life Sci. 276, 119431 (2021).","journal-title":"Life Sci."},{"key":"41660_CR151","doi-asserted-by":"publisher","first-page":"9816","DOI":"10.1002\/jcp.27670","volume":"234","author":"B Mansoori","year":"2019","unstructured":"Mansoori, B. et al. miR-142-3p as tumor suppressor miRNA in the regulation of tumorigenicity, invasion and migration of human breast cancer by targeting Bach-1 expression. J. Cell. Physiol. 234, 9816\u20139825 (2019).","journal-title":"J. Cell. Physiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41660-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41660-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41660-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T22:02:33Z","timestamp":1776290553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-41660-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":151,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["41660"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-41660-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]},"assertion":[{"value":"19 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The studies involving human participants were reviewed and approved by CEIC 2018.280 and 2008\/3123\/I. The patients\/participants provided their written informed consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"12446"}}